23 December 2025 : Original article
Long-Term Prognostic Significance of TACE-Induced Complete Pathological Response in Patients with Hepatocellular Carcinoma Who Have Undergone Liver Transplantation
I-Ji Jeong
BCE 1, Shin Hwang ABCDEF 1*, Chul-Soo Ahn BCF 1, Deok-Bog Moon BCD 1, Tae-Yong Ha BCD 1, Gi-Won Song BCD 1, Dong-Hwan Jung BCD 1, Gil-Chun Park BCD 1, Woo-Hyoung Kang BCD 1, Young-In Yoon BCD 1, Sung-Gyu Lee ABD 1
DOI: 10.12659/AOT.950787
Ann Transplant 2025; 30:e950787
Table 2 Univariate and multivariate analyses of risk factors associated with tumor recurrence and patient survival.
| Parameter | Case No. | Tumor recurrence | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||||
| 5-Year recurrence rate | P-value | Hazard ratio | 95% CI | P-value | ||
| Background liver disease | ND | |||||
| Hepatitis B virus | 201 | 4.2% | 0.095 | |||
| Others | 52 | 0% | ||||
| Preoperative AFP | ND | |||||
| ≤7.5 ng/mL | 148 | 3.6% | 0.872 | |||
| >7.5 ng/mL | 105 | 2.9% | ||||
| Serum PIVKA-II | 0.539 | ND | ||||
| ≤40 mAU/mL | 173 | 4.2% | ||||
| >40 mAU/mL | 59 | 1.9% | ||||
| Maximum diameter of non-viable tumor | 0.012 | |||||
| ≤2.0 cm | 181 | 1.1% | 0.002 | 1 | ||
| >2.0 cm | 72 | 8.7% | 5.22 | 1.48–18.8 | ||
| Number of non-viable tumors | 0.026 | |||||
| 1 | 199 | 2.1% | 0.004 | 1 | ||
| ≥2 | 54 | 7.5% | 3.91 | 1.17–12.9 | ||
| Graft-to-recipient weight ratio | 0.068 | ND | ||||
| ≤0.8 | 25 | 6.2% | ||||
| >0.8 | 228 | 4.7% | ||||
| Background liver disease | 0.186 | ND | ||||
| Hepatitis B virus | 201 | 92.5% | ||||
| Others | 52 | 92.0% | ||||
| Preoperative AFP | ND | |||||
| ≤7.5 ng/mL | 148 | 91.9% | 0.326 | |||
| >7.5 ng/mL | 105 | 94.2% | ||||
| Serum PIVKA-II | 0.535 | ND | ||||
| ≤40 mAU/mL | 173 | 91.9% | ||||
| >40 mAU/mL | 59 | 91.5% | ||||
| Maximum diameter of non-viable tumor | 0.016 | 0.036 | ||||
| ≤2.0 cm | 181 | 94.5% | 1 | |||
| >2.0 cm | 72 | 87.2% | 2.42 | 1.06–5.53 | ||
| Number of non-viable tumors | 0.036 | 0.077 | ||||
| 1 | 199 | 93.4% | 1 | |||
| ≥2 | 54 | 88.7% | 2.02 | 0.98–4.41 | ||
| Graft-to-recipient weight ratio | 0.087 | ND | ||||
| ≤0.8 | 25 | 94.1% | ||||
| >0.8 | 228 | 89.3% | ||||
| 95% CI – 95% confidence interval; AFP – α-fetoprotein; PIVKA-II – protein induced by vitamin K absence or antagonist-II; ND – not done. | ||||||